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ABSTRACT Long-term, low-dose azithromycin reduces exacerbation frequency in chronic obstructive
pulmonary disease (COPD), yet the mechanism remains unclear. This study characterised genome-wide
gene expression changes in patients with neutrophilic COPD following long-term, low-dose azithromycin
treatment.
Patients with neutrophilic COPD (>61% or >162×104 cells per mL sputum neutrophils) were
randomised to receive either azithromycin or placebo for 12 weeks. Sputum and blood were obtained
before and after 12 weeks of treatment. Gene expression was defined using microarrays. Networks were
analysed using the Search Tool for the Retrieval of Interacting Gene database.
In sputum, 403 genes were differentially expressed following azithromycin treatment (171
downregulated and 232 upregulated), and three following placebo treatment (one downregulated and two
upregulated) compared to baseline (adjusted p<0.05 by paired t-test, fold-change >1.5). In blood, 138
genes were differentially expressed with azithromycin (121 downregulated and 17 upregulated), and zero
with placebo compared to baseline (adjusted p<0.05 by paired t-test, fold-change >1.3). Network analysis
revealed one key network in both sputum (14 genes) and blood (46 genes), involving interferon-stimulated
genes, human leukocyte antigens and genes regulating T-cell responses.
Long-term, low-dose azithromycin is associated with downregulation of genes regulating antigen
presentation, interferon and T-cell responses, and numerous inflammatory pathways in the airways and
blood of neutrophilic COPD patients.
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Chronic obstructive pulmonary disease (COPD) is a common illness that poses a major global health
burden [1, 2]. It is characterised by airway neutrophilia, persistent airflow obstruction and exacerbations.
The prevention of exacerbations in COPD is of great importance given their association with lung function
decline, impairment of quality of life, and mortality risk [3–5].
Azithromycin is a macrolide antibiotic used in the treatment of acute, infectious exacerbations of COPD.
Long-term use of low-dose azithromycin has been shown to reduce the number of exacerbations in a
range of respiratory diseases, including asthma [6], COPD [7–9], cystic fibrosis [10, 11] and non-cystic
fibrosis bronchiectasis [12, 13]. Additional benefits include improved lung function in diffuse
panbronchiolitis [14] and bronchiolitis obliterans syndrome [15], and a reduced rate of lung function
decline in cystic fibrosis [11]. While such clinical outcomes are promising for the future management of
these diseases, the underlying mechanism remains unclear.
Macrolides, in addition to their antimicrobial properties, have numerous anti-inflammatory and
immunomodulatory effects. Using microarrays to define how macrolides affect gene expression across the
whole genome will facilitate the understanding of how they impact airway inflammation, and potentially
identify targets for future drug development that do not have the same issues with antibiotic resistance [16].
We hypothesised that 12 weeks of azithromycin treatment would modify gene expression profiles in the
airway and blood of patients with neutrophilic COPD. This study characterised these gene expression
changes using microarrays to identify the underlying molecular mechanisms responsible for the clinical
effects of long-term, low-dose azithromycin in COPD.
Materials and methods
Study design and population
This randomised controlled trial was conducted between April 2009 and December 2011, and clinical and
inflammatory results have been published previously [8]. Recruitment for this study targeted adults with
doctor diagnosed symptomatic COPD, as described in detail previously [8], with stable persistent
neutrophilic inflammation, defined by a sputum differential cell count demonstrating >61% or >162×104
cells per mL neutrophils on two separate occasions (with at least one being the screening visit). These
cut-offs, as well as inclusion and exclusion criteria have been discussed previously [8].
Eligible participants (n=30) were randomly allocated (1:1) to receive oral azithromycin 250 mg daily or
placebo for 12 weeks. In addition to the screening visit, participants attended four visits at monthly
intervals with the final study visit conducted 4 weeks after the end of treatment.
Ethics statement
Participants gave written informed consent. The Hunter New England Area Health Service and University
of Newcastle Research Human Ethics Committees approved the study (06/12/13/3.08 and H-2008-0272)
and it was registered with the Australian New Zealand Clinical Trials Registry ACTRN 12609000259246.
Study protocol
At screening (visit 1) demographics, pre- and post-bronchodilator spirometry, skin-prick testing,
medication history, smoking status, and exhaled carbon monoxide were assessed.
At visit 2 (baseline randomisation) mucus hypersecretion, St George’s Respiratory Questionnaire [17],
symptom visual analogue scores, Clinical COPD Questionnaire [18], and modified Medical Research
Council dyspnoea scale were performed. Induced sputum and peripheral blood (PAXgene Blood RNA
tubes; PreAnalytix, Hombrechtikon, Switzerland) were collected at the baseline randomisation visit and
after 12-weeks of azithromycin or placebo treatment, for gene expression profiling.
Sputum induction and analysis
Sputum was induced at baseline and after the 12-week treatment period with hypertonic saline (4.5%), as
previously described [19]. Selected sputum was dispersed using dithiothreitol for differential cell counts or
stored by placing directly into RLT buffer for RNA extraction. Total cell counts of leukocytes and their
viability were performed on filtered suspensions. Cytospins were prepared, stained (May-Grunwald
Geimsa) and a differential cell count obtained from 400 non-squamous cells. Following centrifugation,
supernatant was stored at −80°C.
Whole-genome gene expression microarrays
RNA was extracted from induced sputum using RNeasy Mini Kits (Qiagen, Hilden, Germany), whereas
peripheral blood collected in PAXgene RNA tubes was extracted using the PAXgene Blood RNA Kit
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(Qiagen) according to the manufacturers’ instructions. RNA was quantitated using Quant-iT RiboGreen
RNA Quantitation Assay Kits (Molecular Probes Inc, Invitrogen, Eugene, OR, USA). A total of 500 ng
RNA was reverse-transcribed into cRNA and biotin-uridine-5′-triphosphate labelled using Illumina
TotalPrep RNA Amplification Kits (Ambion, Austin, TX, USA). A total of 750 ng cRNA was hybridised to
Illumina Sentrix HumanRef-8 Version 2 Expression BeadChips and scanned using an Illumina Bead
Station and captured using BeadScan 3.5.11 (Illumina, San Diego, CA, USA). Samples and gene profiling
results were included in the analysis if the sample was of suitable purity (optical density 260 nm/280 nm:
1.7–2.1) and was successfully amplified (sufficient cRNA generated) and hybridised (95th percentile of
fluorescence score >500) and the data passed quality controls in GeneSpring GX (correlation coefficients
and principle component analysis plots; Agilent Technologies, Santa Clara, CA, USA).
The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus [20] and
are accessible through GEO Series accession number GSE119314 (www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE119314).
Network analysis
We used the Search Tool for the Retrieval of Interacting Genes (STRING) v9.1 (http://string-db.org/) to
identify gene networks amongst our differentially expressed genes. STRING is an online protein–protein
interaction database curated from the literature that predicts associations from systemic genome comparisons.
All network diagrams presented here are based on high confidence scores (>0.7), to retain the highest possible
stringency, as well as at least one network consisting of a node with more than three neighbours.
Statistical methods
Statistical analysis was performed using Stata 11 (StataCorp, College Station, TX, USA). Results are
presented as mean±SD or median (interquartile range) with t-tests for parametric data and Wilcoxon rank
sum tests for nonparametric data. Paired data were analysed using the Wilcoxon signed rank test.
Categorical data were compared using the Chi-squared or Fisher’s exact test as appropriate. p-values <0.05
were considered significant.
Microarray data were exported using Genome Studio (Illumina) and analysed using GeneSpring GX12.5
(Agilent Technologies). Data were log transformed and quantile normalisation performed. Data were
filtered on expression level, and only genes with a raw fluorescence of >250 in all samples were included in
further analysis. Hierarchical clustering analysis was performed using the Euclidean algorithm with Ward’s
linkage. The Euclidian algorithm takes the standard sum of squared distance between two entities. Ward’s
linkage, based on the ANOVA approach, computes the sum of squared errors around the mean for each
cluster, then the two clusters are joined to minimise the increase in error. Differential gene expression
before and after azithromycin treatment or placebo was determined using paired t-tests, and further
filtered on a volcano plot, whereby those genes with adjusted p<0.05 (Benjamini–Hochberg) and
fold-change >1.5 (sputum) or >1.3 (blood) were included. Gene ontology categories and pathways that
were overrepresented in differentially expressed gene lists were determined by using GeneSpring GX12.5
where an adjusted p<0.05 was considered significant.
Results
Sample details
All clinical and inflammatory data has been published previously [8]. Briefly, the mean±SD age was
70±7.6 years, 63.3% were female, and 73.3% were ex-smokers with a mean±SD smoking history of
46.11±36.11 pack-years. The mean±SD forced expiratory volume in 1 s (FEV1) was 53.69±13.74 %
predicted and the mean±SD FEV1/FVC was 57.79±11.24. There were no significant differences in any
clinical or inflammatory parameters between the placebo and azithromycin groups.
Microarray analysis was performed on blood (n=11 azithromycin group; n=12 placebo group) and sputum
(n=11 azithromycin group; n=13 placebo group) in a subset of patients who had paired samples from
baseline and post-treatment visits, as well as sufficient RNA available. Regarding blood samples, five
patients did not have paired samples, and a further two did not have sufficient RNA available for analysis.
Regarding sputum samples, three patients did not have paired samples, and a further three did not have
sufficient RNA available for analysis.
Exacerbation data has been published in detail previously [8]. Of the subset from the original study that
were analysed, six (46.2%) out of 13 in the placebo group and three (21.4%) out of 14 in the azithromycin
group experienced an exacerbation. The median (quartile 1, quartile 3) (range) number of exacerbations
experienced were 0 (0, 1) (0–2) and 0 (0, 0) (0–1) for the placebo and azithromycin groups, respectively.
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Differential gene expression in sputum after azithromycin or placebo treatment
Following azithromycin treatment, the expression of 1877 cRNAs was significantly altered (p<0.05 paired
t-test) compared to baseline. Further filtering on a volcano plot (adjusted p<0.05 paired t-test, fold-change
>1.5) resulted in 667 cRNAs that were differentially expressed. This corresponded to 403 genes that were
differentially expressed (with unannotated, predicted targets and duplicated probes removed) (171
downregulated, 232 upregulated). Gene ontologies for biological processes that were significantly altered
with azithromycin treatment were identified (table 1). Of interest, there were 35 differentially expressed
genes involved in immune system processes and nine genes involved in antigen processing and
presentation (all genes involved in antigen presentation were also involved in immune system processes)
(table 2). Gene expression patterns are detailed in figure 1.
Following treatment with placebo, the expression of 227 cRNAs was significantly altered (p<0.05 paired
t-test) compared to baseline. Further filtering on a volcano plot (adjusted p<0.05 paired t-test, fold-change
>1.5 fold) resulted in only three genes being differentially expressed. These were RASA4P (RAS p21 protein
activator 4, non-coding RNA, 1.56-fold upregulated), ATP6V0D1 (ATPase, H+ transporting, lysosomal
38 kDa, V0 subunit d1 mRNA, 1.56-fold downregulated) and HLA-H (Major histocompatibility complex,
class I, H (pseudogene), non-coding RNA, 1.62-fold upregulated). As the expression of these three genes
were significantly altered following treatment with both azithromycin and placebo, the altered regulation
could not be confidently attributed to azithromycin and they were removed from further analysis.
Differential gene expression in peripheral blood after azithromycin or placebo treatment
Following azithromycin treatment, the expression of 2398 cRNAs was altered (p<0.05 paired t-test)
compared to baseline. Further filtering using a volcano plot (adjusted p<0.05, fold-change >1.5) resulted in
25 cRNAs that were differentially expressed. This corresponded to 22 differentially expressed genes (with
unannotated, predicted targets and duplicated probes removed), far fewer than the number seen in
sputum. All genes were downregulated (supplementary table S1). There were no significant gene ontologies
due to the small number of differentially regulated genes. The use of an identical fold-change cut-off in
blood and sputum was, however, deemed impractical as the concentration of azithromycin is often 10-fold
lower in plasma than in tissues due to its high cellular penetration [21]. Consequently, the fold-change
cut-off was lowered to 1.3 to more accurately reflect this difference, resulting in 166 significantly altered
cRNAs (138 genes). 48 of these genes were involved in immune system processes (table 3). Figure 2 shows
the shift in gene expression profile after azithromycin treatment.
Following treatment with placebo, the expression of 1374 cRNAs was altered (p<0.05 paired t-test)
compared to baseline. However, none of these genes reached significance on filtering using the volcano
plot (adjusted p<0.05 paired t-test, fold-change >1.3).
Network analysis of differentially expressed genes in sputum and blood following azithromycin
To investigate potential pathways underlying the differential gene expression the STRING database was
used. From the 35 genes that were differentially expressed in sputum with a fold-change of >1.5 and
involved in immune system processes and antigen processing and presentation, 33 genes were recognised
by the STRING database. One key network was found that involved 14 genes (figure 3). Key nodes were
TABLE 1 Gene ontology (GO) biological processes altered in the airways with azithromycin
treatment
GO biological process Number of differentially
expressed genes
Adjusted p-value
Translational elongation 28 1.25×10-17
Translation 39 7.99×10-18
Immune response 31 0.004
Energy coupled proton transmembrane transport,
against electrochemical gradient
5 0.012
Cellular macromolecule biosynthetic process 74 0.016
Immune system processes 36 0.017
Macromolecule biosynthetic process 74 0.017
Antigen processing and presentation 9 0.017
Actin filament-based process 15 0.035
Antigen processing and presentation of peptide antigen 6 0.042
Cellular biosynthetic process 85 0.044
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determined by the number of connections with other differentially expressed genes. Those with ⩾3
connections are shown in supplementary table S2.
From the 138 genes that were differentially expressed in blood with a fold-change of >1.3, 135 were
recognised by the STRING database. One key network was found that involved 46 genes (figure 4). Key
nodes were determined by the number of connections with other differentially expressed genes. Those
with ⩾3 connections are shown in supplementary table S3.
Discussion
This study examined the underlying mechanisms of long-term, low-dose azithromycin in neutrophilic
COPD. Patients with stable, neutrophilic COPD were administered either low-dose azithromycin or placebo
TABLE 2 Differentially expressed genes in sputum after azithromycin treatment involved in immune system processes
Gene symbol Gene name p-value Fold change Regulation Probe ID Accession
HLA-H Major histocompatibility complex,
class I, H (pseudogene), non-coding RNA
0.038 2.3 down 1980592 NR_001434.1
HLA-DRB4 Major histocompatibility complex,
class II, DR beta 4
0.045 2.0 down 510079 NM_021983.4
CD83 CD83 molecule, transcript variant 1 0.047 2.0 down 6620026 NM_004233.3
HLA-A Major histocompatibility complex, class I, A 0.038 1.9 down 3400438 NM_002116.5
HLA-DPA1 Major histocompatibility complex,
class II, DP alpha 1
0.049 1.9 down 1190039 NM_033554.2
GBP1 Guanylate binding protein 1, interferon-inducible,
67 kDa
0.039 1.9 down 2190148 NM_002053.1
CFD Complement factor D (adipsin) 0.043 1.9 down 1240152 NM_001928.2
CTSC Cathepsin C, transcript variant 1 0.039 1.8 down 5270367 NM_001814.2
HLA-E Major histocompatibility complex, class I, E 0.041 1.8 down 1030747 NM_005516.4
HLA-B Major histocompatibility complex, class I, B 0.038 1.8 down 5310168 NM_005514.5
ARHGDIB Rho GDP dissociation inhibitor beta 0.045 1.7 down 1570193 NM_001175.4
HLA-DRA Major histocompatibility complex, class II, DR alpha 0.040 1.7 down 2570564 NM_019111.3
CYBB Cytochrome b-245, beta polypeptide 0.038 1.7 down 840168 NM_000397.2
MSN Moesin 0.042 1.7 down 730332 NM_002444.2
CCL23 Chemokine (C-C motif) ligand 23, transcript variant
CKbeta8
0.038 1.6 down 6110343 NM_145898.1
IFI30 Interferon, gamma-inducible protein 30 0.045 1.6 down 2000300 NM_006332.3
CD14 CD14 molecule, transcript variant 1 0.047 1.6 down 7000369 NM_000591.2
CKLF Chemokine-like factor, transcript variant 6 0.043 1.6 down 2760519 NM_001040139.1
GBP2 Guanylate binding protein 2, interferon-inducible 0.041 1.6 down 1940162 NM_004120.3
IFITM3 Interferon induced transmembrane protein 3 (1-8U) 0.044 1.6 down 6650242 NM_021034.2
ITGB2 Integrin, beta 2 (complement component
3 receptor 3 and 4 subunit)
0.045 1.5 down 7200156 NM_000211.1
CD86 CD86 antigen (CD28 antigen ligand 2, B7-2 antigen),
transcript variant 1
0.038 1.5 down 4040022 NM_175862.2
BCAP31 B-cell receptor-associated protein 31 0.038 1.5 down 6450138 NM_005745.6
CCL5 Chemokine (C-C motif) ligand 5 0.038 1.5 down 620717 NM_002985.2
DBNL Drebrin-like, transcript variant 2 0.049 1.5 down 2140671 NM_001014436.1
DCLRE1C DNA cross-link repair 1C (PSO2 homolog,
Saccharomyces cerevisiae), transcript variant b
0.038 2.0 up 6860647 NM_022487.2
FCAR Fc fragment of IgA, receptor for, transcript variant 9 0.049 2.0 up 4250193 NM_133279.1
TNFSF15 Tumor necrosis factor (ligand) superfamily,
member 15
0.043 2.0 up 3370128 NM_005118.2
ZNF160 Zinc finger protein 160, transcript variant 2 0.0378 1.9 up 6980474 NM_198893.1
SPN Sialophorin, transcript variant 1 0.0378 1.8 up 10358 NM_001030288.1
TNFSF14 Tumor necrosis factor (ligand) superfamily, member
14, transcript variant 2
0.048 1.7 up 1170673 NM_172014.1
DCLRE1C DNA cross-link repair 1C (PSO2 homolog,
S. cerevisiae), transcript variant c
0.0388 1.7 up 430044 NM_001033858.1
FCGR3A Fc fragment of IgG, low affinity IIIa, receptor (CD16a),
transcript variant 1
0.0378 1.6 up 4050039 NM_000569.6
LAX1 Lymphocyte transmembrane adaptor 1 0.0378 1.6 up 580411 NM_017773.2
KIR2DS5 Killer cell immunoglobulin-like receptor, two domains,
short cytoplasmic tail, 5
0.0379 1.5 up 2070561 NM_014513.1
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over 12 weeks. Treatment with azithromycin resulted in significant changes in gene profiles in sputum and
blood, including the downregulation of genes associated with antigen presentation, inflammation, and
interferon and T-cell responses. Gene profiles showed only minor changes following treatment with placebo.
COPD exacerbations can be triggered by infectious and non-infectious agents, and the mechanism by
which azithromycin prevents exacerbations is probably complex and multi-factorial. Previous research has
demonstrated that long-term, low-dose azithromycin suppresses pro-inflammatory cytokine production,









FIGURE 1 Microarray clustering of differentially expressed genes in sputum. Genes are clustered in rows,
with red indicating high expression, yellow intermediate expression and blue low expression. Treatment
groups are clustered in columns. Groups are clustered to reflect similarities and differences in gene
expression (as per the Euclidean algorithm with Ward’s linkage). AZM: azithromycin.
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modulates interferon [25–29] and T-cell responses [30, 31]. Importantly, these functions are not universal to
all macrolides (reviewed in [32]), with slight structural differences affecting antimicrobial and
immunomodulatory properties [28].
Our research demonstrated that azithromycin was associated with a downregulation of several human
leukocyte antigen (HLA) molecules in the airways (HLA-A, HLA-B, HLA-DPA1, HLA-DRA and
HLA-DRB4). HLA-A and HLA-B are subtypes of major histocompatibility complex (MHC) class I surface
receptors, while HLA-DPA1, HLA-DRA and HLA-DRB4 are subtypes of MHC class II surface receptors.
MHC class I and II receptors are involved in the presentation of antigens to CD4+ and CD8+ T-cells,
respectively. TAP-1 expression, which is essential for the formation of MHC-I-peptide complexes (reviewed
in [33]) and therefore, for effective antigen presentation to CD8+ T-cells [34], was also downregulated
following treatment with azithromycin. Antigen presentation is a critical step in T-cell activation, and
therefore for the initiation of the adaptive immune responses in general. Consequently, azithromycin may
suppress inflammatory responses in the airways by impairing antigen presentation and therefore limiting the
immune system’s capacity to identify and respond to antigen. The mechanism, however, is unclear.
Azithromycin was also associated with the downregulation of several interferon-stimulated genes in blood
(EIF2AK2, EPSTI, GBP1, GBP2, GBP5, HERC5, IFI16, IFIT1, MX1, OAS1, OAS2, OASL and UBE2L6) and
sputum (GBP1, GBP2, IFI30 and IFITM3). This may be explained by the downregulation of several genes
that are involved in the induction of interferon expression (TRIM25 and IRF7) and interferon signalling
(STAT1 and IRF9). TRIM25 regulates the polyubiquitination of RIG-I, a pattern recognition receptor that
responds to viral dsRNA. This process results in the induction of a signalling cascade, which leads to the
TABLE 3 Differentially expressed genes in blood after azithromycin treatment involved in immune system processes
Gene symbol Gene name p-value Fold change Regulation ProbeID Accession
SYK Spleen tyrosine kinase 0.038 1.8 down 110685 NM_003177.3
HLA-DRB3 Major histocompatibility complex, class II, DR beta 3 0.041 1.8 down 1770504 NM_022555.3
GBP5 Guanylate binding protein 5 0.003 1.7 down 1510364 NM_052942.2
FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64),
transcript variant 1
0.015 1.6 down 2710709 NM_001017986.1
OAS2 2′-5′-oligoadenylate synthetase 2, 69/71 kDa,
transcript variant 1
0.039 1.6 down 7320561 NM_016817.2
OAS1 2′,5′-oligoadenylate synthetase 1, 40/46 kDa,
transcript variant 3
0.004 1.6 down 1090390 NM_001032409.1
IL4R Interleukin 4 receptor, transcript variant 1 0.024 1.5 down 5910609 NM_000418.2
GBP1 Guanylate binding protein 1, interferon-inducible, 67 kDa 0.024 1.5 down 2190148 NM_002053.1
GBP2 Guanylate binding protein 2, interferon-inducible 0.003 1.5 down 1940162 NM_004120.3
TAP1 Transporter 1, ATP-binding cassette, sub-family B 0.020 1.4 down 7330392 NM_000593.5
FYN FYN oncogene related to SRC, FGR, YES,
transcript variant 2
0.039 1.4 down 4860050 NM_153047.1
OASL 2′-5′-oligoadenylate synthetase-like, transcript variant 2 0.044 1.4 down 7650097 NM_198213.1
IL1RN Interleukin 1 receptor antagonist, transcript variant 1 0.036 1.4 down 2470601 NM_173842.1
IFI16 Interferon, gamma-inducible protein 16 0.021 1.4 down 3870594 NM_005531.1
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) 0.038 1.4 down 520086 NM_000566.2
HLA-H Major histocompatibility complex, class I, H
(pseudogene), non-coding RNA.
0.045 1.4 down 5870521 NR_001434.1
LILRB2 Leukocyte immunoglobulin-like receptor, subfamily B,
member 2, transcript variant 2
0.017 1.4 down 540671 NM_001080978.1
PTPRC Protein tyrosine phosphatase, receptor type, C,
transcript variant 4
0.020 1.3 down 6180288 NM_080923.2
IRF7 Interferon regulatory factor 7, transcript variant b 0.004 1.3 down 1470382 NM_004029.2
IL7R Interleukin 7 receptor 0.040 1.3 down 3830349 NM_002185.2
IGSF6 Immunoglobulin superfamily, member 6 0.041 1.3 down 3850202 NM_005849.1
ILF2 Interleukin enhancer binding factor 2, 45 kDa 0.038 1.3 down 5690437 NM_004515.2
OAS1 2′,5′-oligoadenylate synthetase 1, 40/46 kDa,
transcript variant 3
0.047 1.3 down 7040035 NM_001032409.1
HLA-F Major histocompatibility complex, class I, F 0.035 1.3 down 7330053 NM_018950.1
PTPRC Protein tyrosine phosphatase, receptor type, C,
transcript variant 2
0.018 1.4 down 2600408 NM_080921.2
HLA-G HLA-G histocompatibility antigen, class I, G 0.044 1.3 down 2070088 NM_002127.3
BNIP3L BCL2/adenovirus E1B 19 kDa interacting protein 3-like 0.032 1.4 up 2640192 NM_004331.2
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activation of IRF-7, a transcription factor that induces the expression of type-I interferons (IFN-α and
IFN-β). Once interferons are expressed, they are released from the cell and bind to interferon receptors on
the surface of neighbouring cells. Interferon receptor activation induces a signalling cascade that
culminates in the expression of interferon-stimulated genes. Two key transcription factors involved in this
signalling cascade, STAT1 and IRF9, were downregulated following azithromycin treatment. STAT1 forms
a STAT1–STAT1 homodimer to induce the expression of IFN-γ-associated genes, and a STAT1–STAT2









FIGURE 2 Microarray clustering of differentially expressed genes in blood. Genes are clustered in rows, with
red indicating high expression, yellow intermediate expression and blue low expression. Treatment groups are
clustered in columns. Groups are clustered to reflect similarities and differences in gene expression (as per
the Euclidean algorithm with Ward’s linkage). AZM: azithromycin.
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in [35]). Consequently, interferon responses appear to be suppressed at multiple stages following
azithromycin treatment.
As interferon pathways are involved in the induction of inflammatory responses, azithromycin may reduce
exacerbation frequency by limiting the inflammation associated with otherwise benign viral infections. In
addition, as interferons induce MHC-I and -II expression, suppression of interferon pathways may also











FIGURE 3 STRING network of differentially expressed genes in sputum. Connections reflect protein



































FIGURE 4 STRING network of differentially expressed genes in blood. Connections reflect protein interactions
(either physical or functional).
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However, as the induction of interferon responses is typically associated with infection, it is unclear
whether these changes are a direct effect of azithromycin (i.e. through modulation of interferon signalling
pathways) or secondary to a reduced microbial load from anti-microbial activity. While a trend towards a
reduction in bacterial load was observed in these patients, it was not statistically significant [8]. The
original study was, however, insufficiently powered to adequately explore this relationship, and so the
delineation of azithromycin’s immunomodulatory and antimicrobial properties remains unclear.
Previous studies have demonstrated that azithromycin increases viral-induced interferon responses [25, 28, 29].
In the absence of acute infection, however, azithromycin did not affect interferon expression [25, 28, 29],
leading PORTER et al. [28] to suggest that macrolides such as azithromycin may work by “priming”
interferon pathways. Our results indicate that in the absence of acute viral infection, azithromycin acts as a
suppressor of interferon and other inflammatory pathways. Alternatively, a long-term reduction in viral
loads by azithromycin may also explain these results. While azithromycin treatment has been shown to
induce interferons independent of active viral infection, the effect was transient and lost by 24 h [26]. Our
results, taken after 12 weeks of azithromycin treatment, support the notion that this effect is not sustained.
Consequently, it is unlikely that infection-independent induction of interferons plays a role in the efficacy
of long-term azithromycin treatment.
In the airways, azithromycin was associated with the downregulation of the surface receptor CD86, as well as
the cytokines CCL5, CCL23 and CKLF. Through its interaction with CD28, CD86 (B7-2) is a co-stimulatory
molecule required for the activation and continued survival of T-cells. CCL5 (RANTES) [36], CCL23
(MPIF-1) [37] and CKLF [38] are chemokines involved in the chemotaxis of numerous leukocytes including
T-cells, neutrophils and monocytes. These results support previous studies that have shown that
azithromycin supresses T-cell activation [31] and suggest that it may also limit T-cell migration.
Azithromycin was also associated with the downregulation of several other genes involved in immune
signalling, including TNFRSF1B (tumour necrosis factor-α receptor), FCGR1a and FCGR1b (constituents
of the IgG receptor), ILF2 (transcription factor required for the expression of interleukin (IL)-2 by T-cells)
and SYK (a tyrosine kinase involved in B-cell receptor, T-cell receptor and Fc receptor signalling). Most
striking, however, were the effects of azithromycin on the IL-4 signalling pathway, which is critical for
T-helper (Th)2 differentiation. The IL-4 receptor (IL4R) was downregulated, as were STAT6, a
transcription factor activated by the IL-4 receptor that forms STAT6–STAT6 homodimers to induce the
expression of IL-4 stimulated genes, and PARP14, a polymerase that promotes STAT6-dependent
transcription [39, 40]. IRF1, a key transcription factor for Th1 differentiation, was also downregulated.
These results further support the notion that azithromycin suppresses T-cell responses.
In this study, azithromycin treatment resulted in larger fold-changes in gene expression in sputum than in
blood. This is probably due to the high cellular penetration of azithromycin, which can result in tissue
concentrations 10-fold higher than plasma concentrations [21]. These differences are also expected due to
the nature of sputum. As the cells of the airways are exposed to more foreign stimulants than those in
blood, the expression of inflammatory genes should be higher in general. Consequently, when baseline
gene expression is higher, there is a greater capacity for a reduction in gene expression (and therefore a
larger fold-change).
Limitations of this study include the use of mixed cell populations in sputum and blood, which reduced
the ability to pinpoint a possible mechanism of azithromycin, and a small sample size, which
underpowered the study in general. Furthermore, as all patients had neutrophilic COPD, it is not possible
to extrapolate our findings to other respiratory diseases. However, the modulation of universal
inflammatory pathways, such as those seen in this study, may explain why azithromycin demonstrates such
broad efficacy across a range of respiratory diseases.
In summary, this study indicates that long-term, low-dose azithromycin treatment is associated with the
downregulation of genes involved in antigen presentation, interferon and T-cell responses, and numerous
inflammatory pathways. These changes may contribute to the capacity of azithromycin to reduce
exacerbation frequency in COPD, and if so, suggest that it achieves this clinical outcome through broad
modulation of the immune system. This study improves our understanding of azithromycin as an
immunomodulatory agent and provides potential novel targets for future drug development. Further
research is required to determine how azithromycin induces these changes, and whether they can be
achieved without the associated risks of long-term antibiotic use.
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